Back to results
US 2009/0264779 A1Published application
Predicting risk of major adverse cardiac events
AssigneeCritical Care Diagnostics, Inc.
InventorsJames V. Snider, Eugene R. Heyman
Life of this patent
Estimating the term…
Abstract
Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
Claims15
A method for evaluating the risk of a major adverse cardiac event (MACE) for a subject within one year, the method comprising:
- determining a MACE risk score (MACERS) for a subject based upon, at least in part, the ratio of a second level of Growth Stimulation-Expressed Gene 2 (ST2) in the subject at a second time (ST2 T0) to a first level of ST2 in the subject at a first time (ST2 T1), in combination with a weighted logarithm of a level of a natriuretic peptide (NP) in the subject at the second time (NP T1), and
- comparing the MACERS to a reference MACERS;
- wherein the MACERS in comparison with the reference MACERS is indicative of the subject's risk of a MACE within one year.
Dependencies are inferred from the claim text.